All Journals > The Journal of Infectious Diseases > 15 July 2006 > rAls3p‐N vs. rAls1p‐N

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

Science Watch logo

JID Article Named "New Hot Paper" by ScienceWatch.com

Dr. Lauri Hicks' 2007 article on pneumococcal disease has been named a "hot new paper" by Thompson Reuters' ScienceWatch.com. Read a Q&A about the article with Dr. Hicks here. 

Press Release

Unique Collaboration Charts the Migrations of a Parasite that Affected History
Researchers Sequence Louse DNA from Mummies and Propose New Model for its Development


In the News

Featured in Grist
"Another symptom of swine flu: instant amnesia" May 11, 2009
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Read the veterinary literature on swine flu and you get a strong sense of what might be called vaccination treadmill: the hog industry is literally scrambling to generate new vaccines for the rapidly evolving flu strains that sweep through CAFOs. Writing in the Journal of Infectious Diseases [PDF] in 2008, Eileen Thacker and Bruce Janke of Iowa State University paint a stark picture: “A number of genetically diverse viruses are circulating in swine herds throughout the world and are a major cause of concern to the swine industry,” they write. “Influenza virus infections in swine and poultry are potential sources of viruses for the next pandemic among humans.”

Featured in New York Times
"Fear of a Swine Flu Epidemic in 1976 Offers Some Lessons, and Concerns, Today" May 8, 2009
Anti‐Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine‐Associated Guillain‐Barré Syndrome
Irving Nachamkin, Sean V. Shadomy, Anthony P. Moran, Nancy Cox, Collette Fitzgerald, Huong Ung, Adrian T. Corcoran, John K. Iskander, Lawrence B. Schonberger, and Robert T. Chen
Irving Nachamkin, a professor of pathology and laboratory medicine at the University of Pennsylvania, examined some 1976 vaccine that had been saved by a scientist in Texas. In a paper published last year in The Journal of Infectious Diseases, he and colleagues reported that mice given the vaccine made antibodies that reacted with gangliosides, which are components of nerve cells. An antibody attack on gangliosides is part of the disease mechanism of Guillain-Barré.

Featured in AFP
"Swine flu vaccine 'could be ready soon'" May 7, 2009
A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses
Mary A. Hoelscher, Neetu Singh, Sanjay Garg, Lakshmi Jayashankar, Vic Veguilla, Aseem Pandey, Yumi Matsuoka, Jacqueline M. Katz, Ruben Donis, Suresh K. Mittal, and Suryaprakash Sambhara
The vaccine Mittal created for the bird flu worked on three different strains isolated over a seven-year period and was described in papers for the Journal of Infectious Diseases and the journal Clinical Pharmacology and Therapeutics.

Featured in Newsweek
"The Path of a Pandemic" http://www.newsweek.com/id/195692
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Last year researchers from Iowa State University in Ames warned that pigs located in industrial-scale farms were being subjected to influenza infections from farm poultry, wild birds and their human handlers. Writing in The Journal of Infectious Diseases, Eileen Thacker and Bruce Janke said, "As a result of the constantly changing genetic makeup of individual influenza viruses in pigs, the U.S. swine industry is continually scrambling to respond to the influenza viruses circulating within individual production systems."

15 July 2006

Volume 194, Number 2
The Journal of Infectious Diseases 2006;194:256–260
© 2006 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2006/19402-0017$15.00
DOI: 10.1086/504691
BRIEF REPORT

Efficacy of the Anti‐Candida rAls3p‐N or rAls1p‐N Vaccines against Disseminated and Mucosal Candidiasis

Brad J. Spellberg,1,2

Ashraf S. Ibrahim,1,2

Valentina Avanesian,1

Yue Fu,1,2

Carter Myers,1

Quynh T. Phan,1

Scott G. Filler,1,2

Michael R. Yeaman,1,2 and

John E. Edwards, Jr.1,2

1Department of Medicine, Los Angeles Biomedical Research Institute at Harbor–University of California, Los Angeles (UCLA) Medical Center, Torrance, and 2David Geffen School of Medicine at UCLA, Los Angeles

We have shown that vaccination with the recombinant N terminus of Als1p (rAls1p‐N) protects mice against disseminated and oropharyngeal candidiasis. We now report that vaccination of mice with a related candidate, rAls3p‐N, induces a broader antibody response than rAls1p‐N and a similar cell‐mediated immune response. The rAls3p‐N vaccine was equally as effective as rAls1p‐N against disseminated candidiasis but was more effective than rAls1p‐N against oropharyngeal or vaginal candidiasis. Antibody titers did not correlate with protection against disseminated candidiasis, but delayed‐type hypersensitivity did. The rAls3p‐N vaccine is a promising new vaccine candidate for further exploration to prevent systemic and mucosal candidal infections.

Received 2 January 2006; accepted 10 February 2006; electronically published 6 June 2006.

Reprints or correspondence: Dr. Brad Spellberg, Div. of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502 ().

Cited by

Shellee A. Grim, Nina M. Clark. (2009) The role of adjuvant agents in treating fungal diseases. Current Fungal Infection Reports 3:2, 117-126
Online publication date: 1-Jul-2009.
CrossRef
Cristina Cunha Villar, Anna Dongari-Bagtzoglou. (2008) Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis. Expert Reviews in Molecular Medicine 10,
Online publication date: 1-Nov-2008.
CrossRef
Brad Spellberg, Ashraf S. Ibrahim, Lin Lin, Valentina Avanesian, Yue Fu, Peter Lipke, Henry Otoo, Tiffany Ho, and John E. Edwards, Jr.. (2008) Antibody Titer Threshold Predicts Anti‐Candidal Vaccine Efficacy Even though the Mechanism of Protection Is Induction of Cell‐Mediated Immunity. The Journal of Infectious Diseases 197:7, 967-971
Online publication date: 1-Apr-2008.
Abstract-Full Text-PDF Version (217 kB)
Brad Spellberg. (2008) Prospects for and barriers to a fungal vaccine. Expert Opinion on Biological Therapy 7:12, 1785-1788
Online publication date: 1-Jan-2008.
CrossRef
Jim E. Cutler, George S. Deepe Jr, Bruce S. Klein. (2007) Advances in combating fungal diseases: vaccines on the threshold. Nature Reviews Microbiology 5:1, 13-28
Online publication date: 1-Feb-2007.
CrossRef

  • Potential conflicts of interest: B.J.S, A.S.I, Y.F, S.G.F, M.R.Y., and J.E.E. own equity in NovaDigm Therapeutics, Inc., which is developing candidal vaccine technologies. NovaDigm Therapeutics, Inc., provided no financial support for these studies.

    Financial support: Public Health Service (grants R01 AI19990 and AI063382 to J.E.E., K08 AI060641 to B.J.S., R56 AI63503‐01A1 to A.S.I, R01 A1054928 and DE017088 to S.G.F, and R01 AI48031 to M.R.Y.); Bristol Myers Squibb (unrestricted Freedom to Discover Grant for Infectious Disease to J.E.E.); Burroughs Wellcome (New Investigator Award in Molecular Pathogenic Mycology to A.S.I.).

Back to Top
Close Popup